A groundbreaking blood test has been developed, offering a non-invasive and safer method for diagnosing the deadliest form of brain cancer. It potentially eliminates the need for risky surgical procedures.
This blood test focuses on glial tumors including glioblastoma (GBM), and it has been validated in a clinical study published in the International Journal of Cancer.
The study was conducted on brain cancer patients at the Brain Tumor Research Center of Excellence, a collaboration between Imperial College London and Imperial College Healthcare NHS Trust.
Dr. Nelofer Syed, who leads the Center, emphasized the importance of this non-invasive, cost-effective approach for early detection of brain tumors, particularly in diagnosing tumors that are otherwise inaccessible.
Kevin O’Neill, a consultant neurosurgeon at Imperial College, highlighted the potential of this test to accelerate diagnosis and allow surgeons to provide more tailored treatments, thereby improving the chances of survival for patients.
He expressed gratitude towards the participants who contributed to this pivotal study.
The TriNetra-Glio blood test operates by isolating and identifying tumor cells circulating in the blood, providing crucial information with the same level of detail as a tissue sample from a biopsy.
This breakthrough could be especially beneficial for patients with suspected high-grade gliomas, including GBM, astrocytomas, and oligodendrogliomas.
It promises earlier tumor type identification, faster treatment, and potentially higher survival rates, while significantly reducing the need for surgical biopsies that come with considerable risks.
The study has garnered attention from the U.S. Food and Drug Administration (FDA), and there are hopes for a larger study in the UK.
If successful, this could mean patients with suspected high-grade tumors could benefit from this innovation in as little as two years.
Dan Knowles, CEO of Brain Tumor Research, underscored the importance of this research in providing earlier diagnoses and improved outcomes for brain tumor patients.
Given the urgency for new treatments, particularly for GBM which is usually fatal, this development is seen as a critical step in the fight against a disease that is the leading cause of cancer death in UK residents under the age of 40.
The potential to cure this devastating disease seems closer with such innovative advancements in medical technology.
If you care about health, please read studies about berry that can prevent cancer, diabetes, and obesity, and the harm of vitamin D deficiency you need to know.
For more information about health, please see recent studies about the connection between potatoes and high blood pressure, and results showing why turmeric is a health game-changer.
The research findings can be found in International Journal of Cancer.
Copyright © 2024 Knowridge Science Report. All rights reserved.
